Key result
Cardioprotective medication lowers central BP and PWV in adults with congenital heart disease.
Why the study?
Evidence is lacking regarding the efficacy of cardioprotective drugs in improving prognosis for patients with congenital heart disease, who carry a high risk of hypertension and cardiovascular disease.
Do cardioprotective drugs lower central blood pressure and pulse wave velocity in adults with congenital heart disease?
Do cardioprotective drugs lower central blood pressure and pulse wave velocity in adults with congenital heart disease?
In adults with congenital heart disease, cardioprotective medications are associated with lower central systolic blood pressure and arterial stiffness, suggesting potential prognostic benefits in this high-risk population.
Answers are grounded in this paper and cite their sources.
May support vascular benefits of cardioprotective meds in ACHD; hypothesis-generating and requires prospective validation.
Background: At present, there is a paucity of evidence for the efficacy of cardioprotective (CP) drugs in improving the prognosis of patients with congenital heart disease (CHD), who are at high risk of hypertension and cardiovascular disease. CP drugs lower blood pressure (BP); therefore, in the present study we analyzed BP parameters in patients with CHD treated with and without CP drugs.
No takes yet. Share an insight, caveat, or question.
Murakami et al. (2023) studied this question. Cardioprotective medication lowers central blood pressure and pulse wave velocity in adults with congenital heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: